Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06704594

Allopregnanolone and Dynamic GABA-A Receptor Plasticity in Selective Serotonin Reuptake Inhibitor Responsive Premenstrual Dysphoric Disorder

Status
Recruiting
Phase
Phase 4
Study type
Interventional
Enrollment
288 (estimated)
Sponsor
Johns Hopkins University · Academic / Other
Sex
Female
Age
18 Years – 50 Years
Healthy volunteers
Accepted

Summary

Premenstrual dysphoric disorder (PMDD) is a severe affective disorder impacting millions of women worldwide, thought to be due to altered sensitivity to hormone fluctuations across the menstrual cycle. Neuroactive steroid hormones (NAS) and the gamma-aminobutyric acid (GABA)-A receptor (GABAAR) are thought to play a role in PMDD. This research will assess the blood levels of GABAergic NAS, expression of associated enzymes, and expression of GABAAR subunits across the premenstrual (luteal) phase of the menstrual cycle in healthy controls and individuals with PMDD. Within the PMDD group, the investigators will assess how these measures are affected by a low-dose antidepressant medication versus placebo. The results will provide a comprehensive view of the changes in these systems across the menstrual cycle and will add to the investigator's understanding of the mechanisms that underlie PMDD, as well as therapeutic mechanisms of PMDD treatment.

Conditions

Interventions

TypeNameDescription
DRUGsertraline 50 mg dailyThe intervention will be in the form of an oral pill, taken daily, from the day of positive urine ovulation test result until the day of menses onset.
DRUGPlacebo Oral TabletThe placebo oral tablet will be of the same shape, color, and manufacturer as the sertraline 50 mg oral tablets. Tablet will be taken daily, from the day of positive urine ovulation test result until the day of menses onset.

Timeline

Start date
2025-05-14
Primary completion
2029-07-01
Completion
2029-07-01
First posted
2024-11-26
Last updated
2025-06-03

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT06704594. Inclusion in this directory is not an endorsement.